Secukinumab biosimilar - Mabpharm
Alternative Names: CMAB-015Latest Information Update: 07 May 2024
At a glance
- Originator Mabpharm
- Developer Mabpharm; Taizhou Mabtech Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Psoriasis
- Preclinical Ankylosing spondylitis
Most Recent Events
- 03 May 2024 Taizhou Mabtech Pharmaceutical plans a phase III trial for Plaque psoriasis (SC, Injection) in May 2024 (NCT06398652)
- 03 Jun 2023 Taizhou Mabtech Pharmaceutical completes a phase-I trial in Psoriasis (In volunteers) in China (SC) (NCT05734482)
- 28 Feb 2023 Mabpharm plans a clinical trial in Ankylosing spondylitis in China